Fountain secured $6 million Series A-1 financing from Khosla Ventures
GlobeNewswire - 19-May-2020With a total of $11 million, more in vivo preclinical drug testing to be expected
Join the club for FREE to access the whole archive and other member benefits.
Global investment platform
We are a global life sciences investment platform with a long-term capital commitment from the Nan Fung Group. Our team possesses diverse experience with long track records in company formation, venture capital, growth/buyout investments, and drug discovery and development. Through direct investments via Pivotal bioVenture Partners US and Pivotal bioVenture Partners China as well as fund investments, we cover the full spectrum of the life sciences industry including therapeutics, medical devices and diagnostics and across all development stages.
Visit website: https://www.nanfunglifesciences.com/
Details last updated 29-May-2020
With a total of $11 million, more in vivo preclinical drug testing to be expected